• Explore /
  • Poster
  • / Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in <i>BRCA</i> non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01).

Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01).

Abstract Video & Slides Poster

Authors

null

Yoo Na Kim

Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, South Korea

Yoo Na Kim , Boram Park , Je-Gun Joung , Jae-Weon Kim , Byoung-Gie Kim , Sang Wun Kim , Hee Seung Kim , Chel Hun Choi , Myong Cheol Lim , Natalie Yl Ngoi , David Shao Peng Tan , Jung-Yun Lee

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT04361370

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5584)

DOI

10.1200/JCO.2023.41.16_suppl.5584

Abstract #

5584

Poster Bd #

279

Abstract Disclosures

Similar Posters

First Author: Jared Cohen

First Author: Lauren Schaff

First Author: Mansoor Raza Mirza

First Author: Leslie M. Randall